25230-59-5 Usage
Uses
Used in Pharmaceutical Industry:
Methyl 2-formylnicotinate is used as an intermediate in the synthesis of various drugs, contributing to the development of new therapeutic agents.
Used in Antioxidant Applications:
Methyl 2-formylnicotinate is used as an antioxidant agent for its potential to protect cells from oxidative damage, which may contribute to the prevention or treatment of various diseases.
Used in Anti-inflammatory Applications:
Methyl 2-formylnicotinate is used as an anti-inflammatory agent, potentially reducing inflammation and alleviating symptoms associated with inflammatory conditions.
Used in Neurological Disorder Treatment:
Methyl 2-formylnicotinate is used as a therapeutic agent in the treatment of neurological disorders, leveraging its potential neuroprotective properties.
Used in Cancer Treatment:
Methyl 2-formylnicotinate is used as a potential therapeutic agent in cancer treatment, with studies exploring its effects on various types of cancer.
Used in Cardiovascular Disease Treatment:
Methyl 2-formylnicotinate is used as a potential therapeutic agent in the treatment of cardiovascular diseases, possibly contributing to the improvement of heart health.
Used in Food Industry:
Methyl 2-formylnicotinate is used as a flavoring agent, adding a sweet and fruity taste to a variety of food products, enhancing their overall flavor profile.
Check Digit Verification of cas no
The CAS Registry Mumber 25230-59-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,5,2,3 and 0 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 25230-59:
(7*2)+(6*5)+(5*2)+(4*3)+(3*0)+(2*5)+(1*9)=85
85 % 10 = 5
So 25230-59-5 is a valid CAS Registry Number.
25230-59-5Relevant academic research and scientific papers
MODULATORS OF HEMOGLOBIN
-
Paragraph 0218-0219, (2020/06/08)
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION
-
Page/Page column 49, (2012/05/20)
The present invention relates to compounds of formula (IA), (IB) and (IC) and pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these
